Drug Profile
Tanfanercept - HanAll Biopharma
Alternative Names: Anti-TNF-alpha protein - HanAll Biopharma; HBM-9036; HL 036; HL-036337; HL-189 - HanAll Biopharma; TNF-alpha blocker - HanAll BiopharmaLatest Information Update: 26 Mar 2024
Price :
$50
*
At a glance
- Originator HanAll Biopharma
- Developer Daewoong Pharmaceutical; HanAll Biopharma; Harbour BioMed; Unknown
- Class Biobetters; Eye disorder therapies; Recombinant proteins
- Mechanism of Action Tumour necrosis factor alpha inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Phase III Dry eyes
- Preclinical Uveitis
- No development reported Diabetic retinopathy; Wet age-related macular degeneration
Most Recent Events
- 21 Mar 2024 HanAll Biopharma and Daewoong Pharmaceutical successfully conclude discussions with the US FDA to finalize phase 3 VELOS-4 trial design and development plan for Dry eyes, in 2H of 2023
- 26 Oct 2023 HanAll and Daewoong intend to discuss the VELOS-4 study design and development plan with the FDA within the second half of 2023
- 28 Jul 2023 Additional efficacy data from a phase III VELOS-3 trial in Dry eye released by HanAll Biopharma